Home|Best-Bschool-in-india-2018

DSIJ Mindshare

Stock in Focus: This Multibagger Micro-Cap Company Achieves Major Milestone with UNICEF; details inside! Stock in Focus: This Multibagger Micro-Cap Company Achieves Major Milestone with UNICEF; details inside!

Stock in Focus: This Multibagger Micro-Cap Company Achieves Major Milestone with UNICEF; details inside!

The stock is up by 70 per cent in just 1 year and generated multibagger returns of 1,280 per cent in 5 years.

Kiran Shroff 0 952 Article rating: 4.3

The stock is up by 70 per cent in just 1 year and generated multibagger returns of 1,280 per cent in 5 years.

Read more
Low PE stock in focus: This micro-cap company extends its oncology portfolio in South Eastern Europe after an expansion spree in Gulf! Low PE stock in focus: This micro-cap company extends its oncology portfolio in South Eastern Europe after an expansion spree in Gulf!

Low PE stock in focus: This micro-cap company extends its oncology portfolio in South Eastern Europe after an expansion spree in Gulf!

The stock is up by 50 per cent in 6 months and generated multibagger returns of 365 per cent in 5 years.

Kiran Shroff 0 2379 Article rating: 4.2

This approval, for its Enoxaparin product in pre-filled syringes, comes from the largest pharmaceutical market in the Gulf Cooperation Council (GCC) region. This market is projected to grow to USD 13.1 billion by 2031, with a 10-year CAGR of 5.4 per cent.

Read more
Hot Stock: This small-cap scrip hits upper circuit on expansion spree in Gulf; gets Saudi marketing approval for Enoxaparin in PFS! Hot Stock: This small-cap scrip hits upper circuit on expansion spree in Gulf; gets Saudi marketing approval for Enoxaparin in PFS!

Hot Stock: This small-cap scrip hits upper circuit on expansion spree in Gulf; gets Saudi marketing approval for Enoxaparin in PFS!

This market is projected to grow to USD 13.1 billion by 2031, with a 10-year CAGR of 5.4 per cent.

Kiran Shroff 0 1131 Article rating: 4.6

The marketing approval for Enoxaparin in Saudi Arabia is anticipated to pave the way for similar authorizations in other GCC and MENA countries. This anticoagulant holds significance in treating cardiovascular diseases, a notable health concern in Saudi Arabia, and is expected to contribute to the burgeoning global Enoxaparin market.

Read more
Ashish Kacholia's Portfolio multibagger Stock: This small-cap company receives marketing approval from 4 countries for its oncology product! Ashish Kacholia's Portfolio multibagger Stock: This small-cap company receives marketing approval from 4 countries for its oncology product!

Ashish Kacholia's Portfolio multibagger Stock: This small-cap company receives marketing approval from 4 countries for its oncology product!

The stock is up by 50 per cent in 6 months and generated multibagger returns of over 300 per cent in just 3 years.

Kiran Shroff 2 13799 Article rating: 3.8

The shares of the company saw a spurt in volume by more than 1.40 times on BSE. The stock has a PE of 12.03x whereas the sectoral PE is 25.50x.

Read more
RSS
12
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList